Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.3.0.814
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Condensed Consolidated Statements Of Operations        
Product revenue $ 1,821,229 $ 1,347,041 $ 4,596,490 $ 4,370,141
License revenue 31,184 18,889 68,962 56,667
Total Revenues 1,852,413 1,365,930 4,665,452 4,426,808
OPERATING EXPENSES        
Cost of product revenue 1,112,782 867,681 2,808,726 2,785,526
Research and development 2,111,505 1,482,929 5,019,138 7,597,295
Plasma centers 1,214,158 1,018,382 3,359,130 2,641,700
General and administrative expenses 2,078,166 1,035,220 4,861,598 3,711,875
TOTAL OPERATING EXPENSES 6,516,611 4,404,212 16,048,592 16,736,396
LOSS FROM OPERATIONS (4,664,198) (3,038,282) (11,383,140) (12,309,588)
OTHER INCOME (EXPENSE):        
Interest income 11,102 3,508 25,878 8,912
Interest expense (449,328) (335,299) (1,378,778) (904,934)
Change in fair value of stock warrants 0 (14,616) 67,860 (44,196)
Loss on extinguishment of debt 0 0 (719,097) 0
OTHER EXPENSE, NET (438,226) (346,407) (2,004,137) (940,218)
NET LOSS $ (5,102,424) $ (3,384,689) $ (13,387,277) $ (13,249,806)
NET LOSS PER COMMON SHARE - Basic and Diluted $ (0.48) $ (0.36) $ (1.28) $ (1.43)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 10,707,728 9,291,823 10,425,310 9,291,823